InfuSystem (INFU) Q2 2024 earnings summary

Executive summary

• Achieved record quarterly revenue of $33.7 million in Q2 2024, up 6.2% year-over-year, with growth in both Patient Services and Device Solutions segments, marking the 10th record quarter in the last 12.

• Adjusted EBITDA margin improved to 18%, with Adjusted EBITDA of $6.1 million, up over $300,000 year-over-year and significantly higher than Q1 2024.

• Net income for Q2 2024 was $0.7 million, up 64.8% from $0.4 million in Q2 2023; diluted EPS was $0.03.

• Business momentum is strong, with new initiatives and strategic partnerships, including a distribution agreement with Smith+Nephew, expected to drive further growth in the second half of 2024.

• A new $20 million share repurchase program was authorized in May 2024, with $0.3 million repurchased by quarter-end.

Financial highlights

• Net revenue reached $33.7 million, a 6.2% year-over-year increase, overcoming a tough comparison from prior-year negative pressure equipment leases.

• Gross profit was $16.7 million, up 5% year-over-year; gross margin was 49.5%, or 51.1% excluding a $600,000 accrual adjustment.

• Net income for Q2 2024 was $0.7 million; diluted EPS was $0.03.

• Operating cash flow for H1 2024 was $2.7 million; available liquidity stood at $40.5 million as of June 30, 2024.

• Net debt increased to $34 million; leverage ratio under credit agreement capped at 3.5x, with company in compliance.

Outlook and guidance

• Reaffirmed full-year 2024 guidance for high single-digit revenue growth and high teens Adjusted EBITDA margin, above 2023's 17.8%.

• Guidance now includes expected expenses for IT and business application upgrades.

• Management expects continued momentum into H2 2024 and 2025, with sustainable long-term growth and profitability.

• Expect Q3 and Q4 to exceed full-year targets, with momentum from new business wins and ongoing initiatives.

• Management expects adequate liquidity for at least the next year, with available liquidity of $40.5 million as of June 30, 2024.